On Monday, IMPACT THERAP-B surged sharply, jumping over 37% in early trade.

On September 18, the company announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending the approval of the marketing authorization for Sepalna, a maintenance treatment intended for advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

Following the CHMP recommendation, Senaparib will now be submitted to the European Commission for a final decision. If approved by the EC, the drug would be authorized for sale across all EU member states and European Economic Area countries.

The company had previously entered into an exclusive partnership with Pharmanovia in July 2026, granting Pharmanovia exclusive rights to manufacture, develop, and commercialize Senaparib across 66 countries—including all 27 EU member states as well as the UK, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand, and nations across the Middle East and North Africa—for use as a single-agent maintenance therapy for advanced high-grade epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.